Medi-Tate specializes in developing minimally invasive medical devices for the treatment of Benign Prostatic Hyperplasia (BPH), a condition characterized by an enlarged prostate. The company's flagship product, iTind, is a clinically proven device designed to relieve lower urinary tract symptoms caused by BPH. Medi-Tate operates in the medical device market, targeting urologists and healthcare providers who treat patients with BPH. The business model revolves around the development, manufacturing, and distribution of its proprietary medical devices. Revenue is generated through the sale of these devices to healthcare institutions and practitioners globally. Medi-Tate's market presence spans Europe, Asia, and Latin America, leveraging the extensive experience of its leadership team in international sales and marketing of medical technologies. The company aims to provide effective, safe, and patient-friendly solutions that reduce recovery time and improve the quality of life for patients.

Keywords: BPH, iTind, minimally invasive, medical devices, urology, prostate treatment, healthcare, international sales, patient-friendly, recovery time.